Title : Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.

Pub. Date : 2018 Dec

PMID : 30595291






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Despite similar baseline levels, post-procedural cTnI was lower at 8 h (0.13 vs 0.56 ng/ml, p = 0.03) and 24 h (0.2 vs 1.13 ng/ml, p = 0.004) in the TMZ group. Trimetazidine troponin I3, cardiac type Homo sapiens
2 Decline or no change in cTnI was significantly more common in the TMZ group (26% vs 2%, p < 0.01). Trimetazidine troponin I3, cardiac type Homo sapiens
3 Total cTnI released after PCI, as assessed by area under curve was significantly lower in the TMZ group (15.84 vs 3.32 ng h/ml, p = 0.005). Trimetazidine troponin I3, cardiac type Homo sapiens
4 CONCLUSIONS: Oral TMZ started 7 days before PCI was effective in limiting PCI-induced myocardial injury with lower cTnI levels and higher prevalence of TIMI-3 flow. Trimetazidine troponin I3, cardiac type Homo sapiens